Scilex Holding CoSCLXEarnings & Financial Report
Scilex Holding Co is a commercial-stage biopharmaceutical firm focused on developing and commercializing innovative non-opioid pain management therapies for acute and chronic pain segments. It primarily serves the US market, offering prescription and over-the-counter pain relief solutions for patients and healthcare providers.
Revenue
$16.4M
Gross Profit
$12.0M
Operating Profit
$-15.6M
Net Profit
$-37.6M
Gross Margin
73.2%
Operating Margin
-95.4%
Net Margin
-229.6%
YoY Growth
30.1%
EPS
$-7.67
Scilex Holding Co Q2 FY2024 Financial Summary
Scilex Holding Co reported revenue of $16.4M (up 30.1% YoY) for Q2 FY2024, with a net profit of $-37.6M (down 41.0% YoY) (-229.6% margin). Cost of goods sold was $4.4M, operating expenses totaled $27.6M.
Key Financial Metrics
| Total Revenue | $16.4M |
|---|---|
| Net Profit | $-37.6M |
| Gross Margin | 73.2% |
| Operating Margin | -95.4% |
| Report Period | Q2 FY2024 |
Scilex Holding Co Annual Revenue by Year
Scilex Holding Co annual revenue history includes year-by-year totals (for example, 2025 revenue was $30.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $30.3M |
| 2024 | $56.6M |
| 2023 | $46.7M |
| 2022 | $38.0M |
Scilex Holding Co Quarterly Revenue & Net Profit History
Scilex Holding Co results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $4.8M | -67.8% | $-46.1M | -961.9% |
| Q3 FY2025 | $10.6M | -26.8% | $-257.8M | -2441.5% |
| Q2 FY2025 | $9.9M | -39.5% | $-44.0M | -445.1% |
| Q1 FY2025 | $5.0M | -54.0% | $-26.1M | -521.2% |
| Q4 FY2024 | $14.9M | +10.7% | $-6.5M | -43.4% |
| Q3 FY2024 | $14.4M | +42.7% | $-4.4M | -30.4% |
| Q2 FY2024 | $16.4M | +30.1% | $-37.6M | -229.6% |
| Q1 FY2024 | $10.9M | +2.9% | $-24.4M | -224.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.9M | $16.4M | $14.4M | $14.9M | $5.0M | $9.9M | $10.6M | $4.8M |
| YoY Growth | 2.9% | 30.1% | 42.7% | 10.7% | -54.0% | -39.5% | -26.8% | -67.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $91.2M | $104.5M | $100.4M | $93.0M | $79.0M | $83.8M | $275.9M | $365.0M |
| Liabilities | $281.0M | $319.2M | $311.7M | $285.6M | $290.5M | $332.7M | $455.6M | $576.7M |
| Equity | $-189.8M | $-214.7M | $-211.3M | $-192.6M | $-211.5M | $-249.0M | $-176.9M | $-207.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $9.4M | $2.3M | $5.1M | $2.5M | $6.0M | $7.0M | $8.2M | $-17.5M |